METABOLIC STATUS OF VASCULAR ENDOTHELIUM IN PULMONARY TUBERCULOSIS PATIENTS WITH CONCURRENT DIABETES

52 pulmonary tuberculosis patients with concurrent diabetes and 76 pulmonary tuberculosis patients without concurrent diabetes (control group) were examined. The state of vascular endothelium was evaluated by the content of nitrogen oxide (NO), endothelium-1 (E-1) and antigen of Willebrand factor (WF) in blood serum (plasma). Patients with concurrent condition had more significant changes in their metabolic status of vascular endothelium (endothelial dysfunction) compared to control group. It manifested through significant reduction of NO level, which is negatively correlated to the increase of glycosylated hemoglobin and the loss of the self-regulating ability of the endothelium cells. The latter was documented by development of the negative correlation between rates of NO and E-1 (in the comparison group the correlation was positive). Functional decompensation of vascular endothelium in pulmonary tuberculosis patients with concurrent diabetes was accompanied by the presence of endothelial destructive lesions, documented increase of  WF (in the majority of patients from the control group WF was within the upper limit of the referent rates). In 3 months of complex treatment of patients with concurrent pathology NO level became normal, but E-1 and WF went confidently down but still were above the upper limits of the norm.

pulmonary tuberculosis, diabetes, endothelial dysfunction, nitrogen oxide, endothelium-1, Willebrand factor

1. Agapitov L.I., Belozerov Yu.M., Mizernitskiy Yu.L. Endothelium-1 and Willebrand factor in the development of pulmonary hypertension in children with chronic bronchial pulmonary pathology. Clin. Lab. Diagn., 2012, no. 1, pp. 11-13. (In Russ.)

2. Vizir V.A., Berezin A.E., Demidenko A.V. Correlation of  endothelin-1 content in blood plasma with process of heart and arteries remodeling in patients with  arterial hypertension. Ukr. Pulmonolog. Journal, 2003, no. 6, pp. 25-31.

3. Gogin E.E. The choice of treatment tactics of hypertension patients: its individualization, indicators and criteria. Ter. Arkhiv, 2010, no. 12. pp. 5-10. (In Russ.)

4. Golovchenko Yu.I., Treschinskaya M.A. The review of modern understanding about endothelial dysfunction. Epub. www.consilium-medicum.com.ua/issues/1/30/242

5. 5, Kaminskaya G.O., Abdullaev R.Yu., Komissarova O.G. Specifics of metabolic activity of vascular endothelium in pulmonary tuberculosis patients. Vestnik RAMN, 2012, no. 11, pp. 29-33. (In Russ.)

6. Kaminskaya G.O., Abdullaev R.Yu., Komissarova O.G. Evaluation of the functional state of  vascular endothelium in  pulmonary tuberculosis patients as per  results of biochemical testing. Tub., 2013, no. 2, pp. 42-47. (In Russ.)

7. Karoli N.A., Rebrov A.P. Role of endothelium in development of pulmonary hypertension in patients with chronic obstructive pulmonary diseases. Klin.-Lab. Diagn., 2004, – № 8. pp. 8-14. (In Russ.)

8. Kishkun A.A. Rukovodstvo po laboratornym metodam diagnostiki. [Manual on laboratory diagnostics techniques.] Moscow, GEOTAR-Media Publ., 2007.

9. Klinicheskaya interpretatsiya laboratornykh issledovaniy. [Clinical interpretation of laboratory tests]. Ed. by A.B. Belevitin and S.G. Scherbak. St. Petersburg, 2006.

10. Miromanova N.A., Baranchugova T.S. Diagnostic value of laboratory tests of  endothelial dysfunction markers in infectious pathology in children. Klin.-Lab. Diagn., 2013, no. 3, pp. 10-13. (In Russ.)

11. 11, Nasonov E.L., Baranov A.A., Shilkina N.P. Endothelial activation markers (thrombomodulin, Willebrand factor antigen and angiotension-converting enzyme). Clinical value. Klin.-Lab. Diagn., 1998, no. 11, pp. 4-9. (In Russ.)

12. Nikitina V.V., Zakharova N.V., Gladilin G.P. et al. Impact of nitrogen oxide concentration and oxistat activity on the development of inflammatory changes of the vascular wall. Klin.-Lab. Diagn., 2014, no. 5, pp. 11-13. (In Russ.)

13. Polivoda S.N., Cherepok A.A. Willebrand factor as a marker of endothelial dysfunction in patients with cardiac-vascular system. Epub. w.w.w. rheumatology. kiev. ua / wp-content/ uploads/ magazine / 1 / 16.pdf

14. Shestakova M.V., Severin I.S., Dedov I.I. et al. Endothelial relaxation factor in  the  development of  diabetes nephropathy. Vestnik RAMN, 1995, no. 5, pp. 31-34. (In Russ.)

15. Shestakova M.V., Yarek-Martyinova I.R., Ivanishina N.S.et al. Cardiorenal syndrome in diabetes of the 1st type: role of endothelial dysfunction. Kardiologia, 2005, vol. 45, no. 6, pp. 35-41. (In Russ.)

16. Shestakova M.S., Severina A.S., Dedov I.I. Giperglikemiya kak faktor riska sosudistykh oslozhneniy diabeta. V kn. Sakharny diabet: ostrye i khronicheskie oslozhneniya. [Hyperglycemia as  a  risk factor of  vascular complications of diabetes. In: Diabetes: acute and chronic complications]. Ed. by I.I. Dedov and M.V. Shestakov. Moscow, 2011. pp. 59-81.

17. Shestakova M.V. Endothelial dysfunction – is it the cause or consequence of the metabolic syndrome? Epub. rmj.ru/articles-1216.htm

18. Basha B., Samuel S.M., Triggle Ch.R., Ding H. Endothelial dysfunction in  diabetes mellitus: possible involvement of endoplasmatic reticulum stress? Experimental Diabetes Research. – 2012.-doi : 10.1155/2012/481840

19. Benhamou Y., Bellien J., Armengol G. et  al. Assessment of  endothelial function in autoimmune diseases. Rev. Med. Interne., 2014, – doi : 10.1016/j.revmed.2013.12.010

20. Boffa G.M., Zaninotto M., Bacchiega E. et al. Correlation between clinical presentation, brain natriuretic peptide, big endothelin-1, tumor necrosing factor-alpha and troponin in heart failure patients. Ital. Heart J., 2005, vol. 6, pp. 125-132.

21. Christopher D., Mitra S., Sarojini J. et al. Burden of diabetes among patients with tuberculosis: ten-year experience an Indian tertiary care teaching hospital. Int. J. Tuberc. Lung Dis., 2014, vol. 18, suppl.1, pp. s136.

22. van Crevel R., Beiger M., Ottenhoff T.H. et al. Possible mechanisms underlying increased susceptibility of diabetes patients to TB. Int. J. Tuberc. Lung Dis., 2014, vol. 18, suppl. 1, pp. s5.

23. Ding A.H., Nathan C.F., Stuehr D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J.  Immunol., 1988, vol. 141, pp. 2407-2408.

24. Dsa K., Balakrishnan S., Sreenivas A. et al. Screening of tuberculosis patients for diabetes mellitus in Keraka, India: how well are we doing? Int.J. Tuberc. Lung Dis., 2014, vol. 18, suppl. 1, pp. s238.

25. Hadi H.A.R., Suwaidi J.A.I. Endothelial dysfunction in diabetes mellitus. Vascular Health and Risk Management, 2007, vol. 3, no. 6, pp. 853-876.

26. Koesoemadinata R., McAllister S., Livia R. et al. Tuberculosis infection among diabetes mellitus patients in Hasan Sadikin hospital, Bandung, Indonesia. Int. J. Tuberc. Lung Dis., 2014, vol. 18, suppl. 1, pp. s239-s240.

27. Lenting P.J., Denis C.V., Wohner N. von Willebrand factor and thrombosis: risk factor, actor and pharmacological target. Curr. Vas. Pharmacol., 2013, vol. 11, no. 4, pp. 448-456.

28. Miyauchi T., Suzuki N., Kurihara T. et al. Endothelin-1 and endothelin – 3 play different rolts in acute and chronic hemodialysis. Biohem. Biophys.Res. Commun., 1991, vol. 178, pp. 276-281.

29. Ochoa C.D., Wu S., Stevens T. New developments in lung endothelial heterogeneity: von Willebrand factor, P-selectin and the Weibel-Palade body. Semin. Thromb. Hemost., 2010, vol. 36, no. 3, pp. 301-308.

30. van den Oever I.A.M., Raterman H.G., Nurmohamed M.T. et al. Endothelial dysfunction, inflammation and  apoptosis in  diabetes mellitus. Mediators of  Inflammation. 2010, – doi :10.1155/ 2010/ 792393.

31. Page A.V., Liles W.C. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence, 2013, vol. 4, no. 6, pp. 507-516.

32. Paulus P., Jennewein C., Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Biomarkers, 2011, vol. 16, s.1. pp. s11-s21.

33. Rao R.M., Yang L., Garcia-Gardena G. et al. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ. Res., 2007, vol. 101, pp. 234-247.

34. Rauch A., Wohner N., Christopher O.D. et al. On the versatility of von Willebrand factor. Mediterr. J. Hematol., Infect. Dis., 2013, vol. 5, no. 1, e.2013046, doi: 10.4084/MJHID.1013.046.Print 2013.

35. Ruslami R., Ugarte-gil C., Walzl G. et  al. TANDEM field studies on  TB and  diabetes mellitus in Peru, South Africa, Romania and Indonesia. Int.J. Tuberc. Lung Dis., 2014, vol. 18, suppl. 1, pp. s6.

36. Subramaniyam D., Virtala R., Pawlowski K. et al. Alpha 1-fntitrypsin modulates TNF-alpha induced gene expression in lung microvascular endothelial cells. Eur. Respir. J., 2007, vol. 30, suppl. 51, pp. s788.

37. Tabit C.E., Chung W.B., Hamburg N.M. et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev. Endocr. Metab. Disord., 2010, vol. 11, no. 1, pp. 61-74.

38. Wu Z.Y., Guo J.T., Huang Y. et  al. Impact of  diabetes mellitus on  clinicfl presentation and treatment outcome of pulmonary tuberculosis in an urban area in China. Int. J. Tuberc. Lung Dis., 2014, vol. 18, suppl. 1, pp. s240.

39. Xu J., Zou M.-H. Molecular insights and  therapeutic targets for  diabetic endothelial dysfunction. Circulation, 2009, vol. 120, no. 13, pp. 1266-1286.